Clostridium difficile-associated disease.
Heins
Jodi R
JR
Department of Pharmacy Practice, South Dakota State University, Sioux Falls, South Dakota, USA.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D016360:Clostridioides difficile / Q000145:classification / Q000472:pathogenicity; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology / Q000382:microbiology* / Q000628:therapy*; D004791:Enzyme Inhibitors; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage; D019936:Probiotics / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D012008:Recurrence; D012307:Risk Factors; D012440:Saccharomyces; D014640:Vancomycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D008795:Metronidazole; D014640:Vancomycin